Abdominal Chemotherapy for Ovarian Cancer Improves Survival
Women who received chemotherapy directly in their abdomens as part of treatment for advanced ovarian cancer lived more than a year longer than women who received the same chemotherapy intravenously, researchers reported last week.
The findings confirm and expand recent research showing that intraperitoneal (IP) chemotherapy, which delivers drugs directly to the abdominal cavity through a catheter, can significantly increase survival for some women with the disease.
In the study, women who received chemotherapy intravenously and through an IP route lived on average 16 months longer than women who had IV chemotherapy only, according to findings in the January 5 New England Journal of Medicine (NEJM). Read more
Guest Update by Dr. John E. Niederhuber
Supporting Cancer Drug Development
NCI has an important role to play in the drug development process in the United States. From its expansive clinical trials program to the drug discovery research it performs and funds, the institute believes it has an essential duty to expedite the discovery and development of interventions that will save lives.
Outside of academic and industry circles, very little attention is paid to the multiplicity of steps and tasks required to take a molecule of interest or a therapeutic vaccine concept from initial laboratory investigations to preparation of patient-grade agents ready for testing in appropriate patients. But the public expects - and we want to deliver - more effective and less toxic interventions to prevent and treat cancer, and we are determined to dramatically increase the speed of this process. Read more